Elizabeth Ramsay1, Charles Mougenot2, Robert Staruch3, Aaron Boyes1, Mohammad Kazem1, Michael Bronskill1, Harry Foster4, Linda Sugar5, Masoom Haider6, Laurence Klotz7, Rajiv Chopra8. 1. Physical Sciences Platform, Sunnybrook Research Institute, Toronto, Ontario, Canada. 2. Philips, Markham, Ontario, Canada. 3. Philips Research North America, Cambridge, Massachusetts. 4. Department of Anaesthesiology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto. 5. Department of Anatomic Pathology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada. 6. Department of Medical Imaging, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada. 7. Department of Urology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada. 8. Department of Radiology and Advanced Imaging Research Center, University of Texas Southwestern Medical Center, Dallas, Texas. Electronic address: Rajiv.chopra@utsouthwestern.edu.
Abstract
PURPOSE: We evaluated magnetic resonance imaging controlled transurethral ultrasound therapy as a treatment for magnetic resonance imaging defined focal prostate cancer using subsequent prostatectomy and histology as the reference standard. MATERIALS AND METHODS: Five men completed this pilot study, which was approved by the institutional review board. Prior to radical prostatectomy focal tumors identified by magnetic resonance imaging were treated by coagulating targeted subtotal 3-dimensional volumes of prostate tissue using magnetic resonance imaging controlled transurethral focused ultrasound. Treatment was performed with a 3 Tesla clinical magnetic resonance imaging unit combined with modified clinical planning software for high intensity focused ultrasound therapy. After prostatectomy whole mount histological sections parallel to the magnetic resonance imaging treatment planes were used to compare magnetic resonance imaging measurements with thermal damage at the cellular level and, thus, evaluate treatment and target accuracy. RESULTS: Three-dimensional target volumes of 4 to 20 cc and with radii up to 35 mm from the urethra were treated successfully. Mean ± SD temperature control accuracy at the target boundary was -1.6 ± 4.8C and the mean spatial targeting accuracy achieved was -1.5 ± 2.8 mm. Mean treatment accuracy with respect to histology was -0.4 ± 1.7 mm with all index tumors falling inside the histological outer limit of thermal injury. CONCLUSIONS: Magnetic resonance imaging guided transurethral ultrasound therapy is capable of generating thermal coagulation and tumor destruction in targeted 3-dimensional angular sectors out to the prostate capsule for prostate glands up to 70 cc in volume. Ultrasound parameters needed to achieve ablation at the prostate capsule were determined, providing a foundation for future studies. Copyright Â
PURPOSE: We evaluated magnetic resonance imaging controlled transurethral ultrasound therapy as a treatment for magnetic resonance imaging defined focal prostate cancer using subsequent prostatectomy and histology as the reference standard. MATERIALS AND METHODS: Five men completed this pilot study, which was approved by the institutional review board. Prior to radical prostatectomy focal tumors identified by magnetic resonance imaging were treated by coagulating targeted subtotal 3-dimensional volumes of prostate tissue using magnetic resonance imaging controlled transurethral focused ultrasound. Treatment was performed with a 3 Tesla clinical magnetic resonance imaging unit combined with modified clinical planning software for high intensity focused ultrasound therapy. After prostatectomy whole mount histological sections parallel to the magnetic resonance imaging treatment planes were used to compare magnetic resonance imaging measurements with thermal damage at the cellular level and, thus, evaluate treatment and target accuracy. RESULTS: Three-dimensional target volumes of 4 to 20 cc and with radii up to 35 mm from the urethra were treated successfully. Mean ± SD temperature control accuracy at the target boundary was -1.6 ± 4.8C and the mean spatial targeting accuracy achieved was -1.5 ± 2.8 mm. Mean treatment accuracy with respect to histology was -0.4 ± 1.7 mm with all index tumors falling inside the histological outer limit of thermal injury. CONCLUSIONS: Magnetic resonance imaging guided transurethral ultrasound therapy is capable of generating thermal coagulation and tumor destruction in targeted 3-dimensional angular sectors out to the prostate capsule for prostate glands up to 70 cc in volume. Ultrasound parameters needed to achieve ablation at the prostate capsule were determined, providing a foundation for future studies. Copyright Â
Authors: Steffen Sammet; Ari Partanen; Ambereen Yousuf; Christina L Sammet; Emily V Ward; Craig Wardrip; Marek Niekrasz; Tatjana Antic; Aria Razmaria; Keyvan Farahani; Shunmugavelu Sokka; Gregory Karczmar; Aytekin Oto Journal: World J Radiol Date: 2015-12-28
Authors: M Minhaj Siddiqui; Soroush Rais-Bahrami; Baris Turkbey; Arvin K George; Jason Rothwax; Nabeel Shakir; Chinonyerem Okoro; Dima Raskolnikov; Howard L Parnes; W Marston Linehan; Maria J Merino; Richard M Simon; Peter L Choyke; Bradford J Wood; Peter A Pinto Journal: JAMA Date: 2015-01-27 Impact factor: 56.272
Authors: Ari Partanen; Nitin K Yerram; Hari Trivedi; Matthew R Dreher; Juha Oila; Anthony N Hoang; Dmitry Volkin; Jeffrey Nix; Baris Turkbey; Marcelino Bernardo; Diana C Haines; Compton J Benjamin; W Marston Linehan; Peter Choyke; Bradford J Wood; Gösta J Ehnholm; Aradhana M Venkatesan; Peter A Pinto Journal: BJU Int Date: 2013-06-07 Impact factor: 5.588
Authors: Joseph L Chin; Michele Billia; James Relle; Matthias C Roethke; Ionel V Popeneciu; Timur H Kuru; Gencay Hatiboglu; Maya B Mueller-Wolf; Johann Motsch; Cesare Romagnoli; Zahra Kassam; Christopher C Harle; Jason Hafron; Kiran R Nandalur; Blaine A Chronik; Mathieu Burtnyk; Heinz-Peter Schlemmer; Sascha Pahernik Journal: Eur Urol Date: 2016-01-06 Impact factor: 20.096
Authors: David Bonekamp; M B Wolf; M C Roethke; S Pahernik; B A Hadaschik; G Hatiboglu; T H Kuru; I V Popeneciu; J L Chin; M Billia; J Relle; J Hafron; K R Nandalur; R M Staruch; M Burtnyk; M Hohenfellner; H-P Schlemmer Journal: Eur Radiol Date: 2018-06-25 Impact factor: 5.315
Authors: Mikael Anttinen; Pietari Mäkelä; Antti Viitala; Pertti Nurminen; Visa Suomi; Teija Sainio; Jani Saunavaara; Pekka Taimen; Roberto Blanco Sequeiros; Peter J Boström Journal: Eur Urol Open Sci Date: 2020-11-25